• slidebg1

    "I have known and admired the Abingworth team for many years and have relished the opportunity to partner with them at Chiasma. 
    Their unique combination of analytic insights and business judgment, deriving from their extensive real world operating experience,
    enables them to support management teams and portfolio companies in ways that set them apart from most venture firms."

    Mark Leuchtenberger, President and CEO of Chiasma

  • slidebg1

    "Working with Abingworth to build CRISPR Therapeutics is a pleasure.
    They are incredibly supportive in shaping the company, which aims to lead the highly dynamic and competitive environment of gene editing."

    Rodger Novak, CEO of CRISPR Therapeutics

  • slidebg1

    "Abingworth has been an incredible partner.
    Their real-world operating experience allows companies to execute at the highest levels.
    Gynesonics would not be where we are today without their tremendous support."

    Chris Owens, CEO of Gynesonics

  • slidebg1

    "We are proud to call Abingworth partners. Their counsel along with their strategic thinking,
    especially around our M&A activities, has proven to be invaluable."

    Bob Strickland, CEO of InMediata

  • slidebg1

    "Abingworth’s involvement in Magellan Diagnostics has helped us to rapidly expand our product portfolio and reach. 
    Their guidance has been instrumental in the expansion of our strategic vision and our accelerating growth."

    Amy Winslow, President of Magellan Diagnostics

  • slidebg1

    "Abingworth's broader role truly distinguished it from other investors.
    Because of this, Abingworth is the first venture firm that I would contact when
    planning my next company."

    John West, CEO of Personalis and former CEO of Solexa

  • slidebg1

    "Abingworth has been an active, knowledgeable and supportive investor.
    They played an instrumental role in bringing together some of the key innovative technologies
    used to develop our bionic vision restoration programmes as well as being very active in the fundraising and IPO process."

    Khalid Ishaque, CEO of Pixium Vision

  • slidebg1

    "The full Abingworth team has been of great support throughout the growth of our company, by providing quality services
    on legal, scientific, human resources, communication and financial matters, as well as their strategic role as a sparring partner
    in our development. Together with us, they went the extra mile in every single step and I warmly recommend them."

    Hans Schikan, former CEO of Prosensa

  • slidebg1

    "I was impressed by Abingworth’s thoughtful, candid and rigorous diligence process,
    and their interest in building a relationship with management before they became investors. 
    That approach created mutual understanding and trust, and laid the foundation for a highly productive partnership."

    Timothy Noyes, President and CEO of Proteon Therapeutics

  • slidebg1

    "Abingworth not only devised and executed a thorough diligence process, but as our lead Series A investor,
    galvanized a strong long-term investor syndicate. Through their expansive network, they also helped us secure the site
    of our new corporate headquarters in an intensely competitive real estate market."

    Grant Pickering, President and CEO of SutroVax

  • slidebg1

    "I feel fortunate to have Abingworth as an investor in Wilson Therapeutics.
    Their in-depth knowledge of drug development in combination with being
    very well connected in the life science industry adds great value to our company."

    Jonas Hansson, CEO of Wilson Therapeutics

  • slidebg1

    "Abingworth led the initial investment in Avila when it was little more than a few scientists with a new idea
    - an idea that challenged the prevailing conventional wisdom about how to make new medicines.
    It took vision on Abingworth's part to make that kind of commitment, and they were right."

    Katrine Bosley, Former CEO of Avila Therapeutics

Venture Capital

With almost 30 years of experience investing in novel life science technologies, we understand how challenging it can be to turn a great idea into a great company. We are comfortable evaluating and taking significant scientific risks. Our team and network of advisors includes a number of former executives with first-hand experience of these challenges, who are available to provide support and advice when it is needed.

We also understand that building a successful company takes time and patience. Our team is committed to building real value over the long-term.

 

Case Studies

Home

About Us

  1. About Us
  2. Our Team
  3. Transatlantic Reach
  4. Funds

Strategy

  1. Our Strategy
  2. Venture Capital
  3. Clinical Co‑development
  4. VIPEs
  5. Public Markets

Portfolio

  1. Portfolio Companies
  2. Case Studies

Media Centre

  1. Recent News
  2. Archived News
  3. Film

Contact

  1. Contact Us
  2. Send Us Your Proposal
Venture Capital

With almost 30 years of experience investing in novel life science technologies, we understand how challenging it can be to turn a great idea into a great company. We are comfortable evaluating and taking significant scientific risks. Our team and network of advisors includes a number of former executives with first-hand experience of these challenges, who are available to provide support and advice when it is needed.

We also understand that building a successful company takes time and patience. Our team is committed to building real value over the long-term.

Case Studies

 
Copyright Abingworth 2017